Total Payments
$215,312
2024 Payments
$134.78
Companies
11
Transactions
13
Medicare Patients
24,311
Medicare Billing
$1.6M
Payment Breakdown by Category
Royalty/License$214,833 (99.8%)
Food & Beverage$479.33 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $214,833 | 3 | 99.8% |
| Food and Beverage | $479.33 | 10 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aclaris Therapeutics, Inc. | $214,833 | 3 | $0 (2019) |
| Celgene Corporation | $91.00 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $90.39 | 1 | $0 (2022) |
| Janssen Scientific Affairs, LLC | $86.52 | 1 | $0 (2019) |
| Incyte Corporation | $59.73 | 1 | $0 (2024) |
| Verrica Pharmaceuticals Inc. | $51.28 | 1 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $33.20 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $23.77 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $15.31 | 1 | $0 (2017) |
| AbbVie, Inc. | $14.67 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $134.78 | 3 | Incyte Corporation ($59.73) |
| 2022 | $123.59 | 2 | Novartis Pharmaceuticals Corporation ($90.39) |
| 2019 | $215,011 | 5 | Aclaris Therapeutics, Inc. ($214,833) |
| 2017 | $43.44 | 3 | Janssen Biotech, Inc. ($15.31) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $51.28 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $59.73 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $23.77 | General |
| Category: Immunology | ||||||
| 10/21/2022 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $33.20 | General |
| Category: Dermatology | ||||||
| 10/20/2022 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $90.39 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2019 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $91.00 | General |
| 10/18/2019 | Janssen Scientific Affairs, LLC | Tremfya (Drug) | Food and Beverage | In-kind items and services | $86.52 | General |
| Category: Immunology | ||||||
| 10/10/2019 | Aclaris Therapeutics, Inc. | RHOFADE (Drug) | Royalty or License | Cash or cash equivalent | $105,888.19 | General |
| Category: DERMATOLOGY | ||||||
| 07/01/2019 | Aclaris Therapeutics, Inc. | RHOFADE (Drug) | Royalty or License | Cash or cash equivalent | $83,381.34 | General |
| Category: DERMATOLOGY | ||||||
| 03/21/2019 | Aclaris Therapeutics, Inc. | RHOFADE (Drug) | Royalty or License | Cash or cash equivalent | $25,563.60 | General |
| Category: DERMATOLOGY | ||||||
| 08/29/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Immunology | ||||||
| 06/14/2017 | Regeneron Healthcare Solutions, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/28/2017 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 6,058 | 14,623 | $934,832 | $396,965 |
| 2022 | 35 | 6,048 | 14,316 | $953,660 | $404,842 |
| 2021 | 36 | 6,146 | 14,785 | $973,559 | $426,170 |
| 2020 | 33 | 6,059 | 14,717 | $912,375 | $364,002 |
Total Patients
24,311
Total Services
58,441
Medicare Billing
$1.6M
Procedure Codes
134
All Medicare Procedures & Services
134 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,452 | 1,866 | $243,650 | $106,568 | 43.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 1,245 | 1,561 | $149,712 | $50,363 | 33.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 503 | 596 | $95,721 | $40,911 | 42.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 1,018 | 8,560 | $80,209 | $40,150 | 50.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 314 | 347 | $49,904 | $20,068 | 40.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 159 | 172 | $41,495 | $18,738 | 45.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 110 | 143 | $36,623 | $15,283 | 41.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 219 | 219 | $35,589 | $14,275 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 153 | $28,301 | $12,073 | 42.7% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 76 | 91 | $24,662 | $11,798 | 47.8% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 63 | 68 | $20,083 | $9,341 | 46.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 177 | 201 | $16,320 | $7,478 | 45.8% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 56 | 58 | $15,008 | $7,022 | 46.8% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 85 | 89 | $15,470 | $6,528 | 42.2% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 51 | 53 | $10,384 | $4,792 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $9,934 | $4,473 | 45.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 66 | 111 | $7,941 | $4,152 | 52.3% |
| 11306 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 44 | 44 | $7,730 | $3,574 | 46.2% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 40 | 40 | $6,639 | $3,013 | 45.4% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 20 | 21 | $4,113 | $2,127 | 51.7% |
| 17271 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 19 | 23 | $5,502 | $2,092 | 38.0% |
| 11307 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 20 | 21 | $4,189 | $1,849 | 44.1% |
| 17273 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | Office | 2023 | 11 | 12 | $3,611 | $1,765 | 48.9% |
| 69100 | Biopsy of ear | Office | 2023 | 33 | 35 | $4,832 | $1,693 | 35.0% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 20 | 20 | $3,593 | $1,649 | 45.9% |
About Dr. Andrew Ondo, M.D
Dr. Andrew Ondo, M.D is a Dermatology healthcare provider based in Las Cruces, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275536559.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Ondo, M.D has received a total of $215,312 in payments from pharmaceutical and medical device companies, with $134.78 received in 2024. These payments were reported across 13 transactions from 11 companies. The most common payment nature is "Royalty or License" ($214,833).
As a Medicare-enrolled provider, Ondo has provided services to 24,311 Medicare beneficiaries, totaling 58,441 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 134 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Las Cruces, NM
- Active Since 05/31/2005
- Last Updated 05/10/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1275536559
Products in Payments
- RHOFADE (Drug) $214,833
- COSENTYX (Biological) $90.39
- Tremfya (Drug) $86.52
- OPZELURA (Drug) $59.73
- YCANTH (Drug) $51.28
- ILUMYA (Biological) $33.20
- Sotyktu (Drug) $23.77
- STELARA (Biological) $15.31
- Humira (Biological) $14.67
- DUPIXENT DUPILUMAB INJECTION (Biological) $13.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.